Altimmune
Compare Altimmune…Clinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AltimmuneClinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.